Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	B-protein
factors	I-protein
YY1	B-protein
and	O
LSF	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O

A	O
subpopulation	O
of	O
stably	B-cell_type
infected	I-cell_type
CD4+	I-cell_type
cells	I-cell_type
capable	O
of	O
producing	O
virus	O
upon	O
stimulation	O
has	O
been	O
identified	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
individuals	O
(	O
T.-W.Chun	O
,	O
D.Finzi	O
,	O
J.Margolick	O
,	O
K.Chadwick	O
,	O
D.Schwartz	O
,	O
and	O
R.F.Siliciano	O
,	O
Nat.Med.1	O
:	O
1284-1290	O
,	O
1995	O
)	O
.	O

Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O

YY1	B-protein
,	O
a	O
widely	O
distributed	O
human	B-protein
transcription	I-protein
factor	I-protein
,	O
is	O
known	O
to	O
inhibit	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
transcription	O
and	O
virus	O
production	O
.	O

LSF	B-protein
(	O
also	O
known	O
as	O
LBP-1	B-protein
,	O
UBP	B-protein
,	O
and	O
CP-2	B-protein
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	B-protein
has	O
no	O
effect	O
on	O
LTR	B-DNA
activity	O
in	O
vivo	O
.	O

We	O
report	O
that	O
both	O
YY1	B-protein
and	O
LSF	B-protein
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

Further	O
,	O
we	O
have	O
found	O
that	O
these	O
factors	O
cooperate	O
in	O
the	O
repression	O
of	O
LTR	B-DNA
expression	O
and	O
viral	O
replication	O
.	O

This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	B-protein
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O

Through	O
this	O
mechanism	O
of	O
gene	O
regulation	O
,	O
YY1	B-protein
and	O
LSF	B-protein
could	O
contribute	O
to	O
the	O
establishment	O
and	O
maintenance	O
of	O
a	O
population	O
of	O
cells	O
stably	O
but	O
nonproductively	O
infected	O
with	O
HIV-1	O
.	O

JOURNAL	NULL
OF	NULL
ViROLOGY	NULL
,	NULL
Dec.	NULL
1997	NULL
,	NULL
p.	NULL
9375-9382	NULL
0022-538	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

71	NULL
,	NULL
No	NULL
.	NULL

12	NULL
Repression	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
through	NULL
the	NULL
Novel	NULL
Cooperation	NULL
of	NULL
Human	NULL
Factors	NULL
YY1	NULL
and	NULL
LSF	NULL
FABIO	NULL
ROMERIO	NULL
,	NULL
MATTHEW	NULL
N.	NULL
GABRIEL	NULL
,	NULL
anp	NULL
DAVID	NULL
M.	NULL
MARGOLIS*	NULL
Institute	NULL
of	NULL
Human	NULL
Virology	NULL
,	NULL
Medical	NULL
Biotechnology	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Maryland	NULL
Biotechnology	NULL
Institute	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21201	NULL
Received	NULL
7	NULL
April	NULL
1997/Accepted	NULL
20	NULL
August	NULL
1997	NULL
A	NULL
subpopulation	NULL
of	NULL
stably	NULL
infected	NULL
CD4*	NULL
cells	NULL
capable	NULL
of	NULL
producing	NULL
virus	NULL
upon	NULL
stimulation	NULL
has	NULL
been	NULL
identified	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-positive	NULL
individuals	NULL
(	NULL
T.-W.	NULL
Chun	NULL
,	NULL
D.	NULL
Finzi	NULL
,	NULL
J.	NULL
Margolick	NULL
,	NULL
K.	NULL
Chadwick	NULL
,	NULL
D.	NULL
Schwartz	NULL
,	NULL
and	NULL
R.	NULL
F.	NULL
Siliciano	NULL
,	NULL
Nat	NULL
.	NULL

Med	NULL
.	NULL

1:1284-1290	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

Few	NULL
host	NULL
factors	NULL
that	NULL
directly	NULL
limit	NULL
HIV-1	NULL
transcription	NULL
and	NULL
could	NULL
support	NULL
this	NULL
state	NULL
of	NULL
nonproductive	NULL
HIV-1	NULL
infection	NULL
have	NULL
been	NULL
described	NULL
.	NULL

YY1	NULL
,	NULL
a	NULL
widely	NULL
distributed	NULL
human	NULL
transcription	NULL
factor	NULL
,	NULL
is	NULL
known	NULL
to	NULL
inhibit	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
transcription	NULL
and	NULL
virus	NULL
production	NULL
.	NULL

LSF	NULL
(	NULL
also	NULL
known	NULL
as	NULL
LBP-1	NULL
,	NULL
UBP	NULL
,	NULL
and	NULL
CP-2	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
LTR	NULL
transcription	NULL
in	NULL
vitro	NULL
,	NULL
but	NULL
transient	NULL
expression	NULL
of	NULL
LSF	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
LTR	NULL
activity	NULL
in	NULL
vivo	NULL
.	NULL

We	NULL
report	NULL
that	NULL
both	NULL
YY1	NULL
and	NULL
LSF	NULL
participate	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
complex	NULL
that	NULL
recognizes	NULL
the	NULL
initiation	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Further	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
these	NULL
factors	NULL
cooperate	NULL
in	NULL
the	NULL
repression	NULL
of	NULL
LTR	NULL
expression	NULL
and	NULL
viral	NULL
replication	NULL
.	NULL

This	NULL
cooperative	NULL
function	NULL
may	NULL
account	NULL
for	NULL
the	NULL
divergent	NULL
effects	NULL
of	NULL
LSF	NULL
previously	NULL
observed	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
cooperation	NULL
of	NULL
two	NULL
general	NULL
cellular	NULL
transcription	NULL
factors	NULL
may	NULL
allow	NULL
for	NULL
the	NULL
selective	NULL
downregulation	NULL
of	NULL
HIV	NULL
transcription	NULL
.	NULL

Through	NULL
this	NULL
mechanism	NULL
of	NULL
gene	NULL
regulation	NULL
,	NULL
YY1	NULL
and	NULL
LSF	NULL
could	NULL
contribute	NULL
to	NULL
the	NULL
establishment	NULL
and	NULL
maintenance	NULL
of	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
stably	NULL
but	NULL
nonproductively	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

The	NULL
paradigm	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
transcriptional	NULL
activation	NULL
and	NULL
virion	NULL
production	NULL
following	NULL
cellular	NULL
stimulation	NULL
has	NULL
been	NULL
long	NULL
established	NULL
.	NULL

The	NULL
nuclear	NULL
level	NULL
of	NULL
several	NULL
cellular	NULL
factors	NULL
,	NULL
most	NULL
notably	NULL
NF-kB	NULL
,	NULL
is	NULL
upregulated	NULL
following	NULL
antigen-	NULL
or	NULL
lec-tin-induced	NULL
lymphocyte	NULL
activation	NULL
,	NULL
allowing	NULL
HIV-1	NULL
mRNA	NULL
expression	NULL
and	NULL
successful	NULL
production	NULL
of	NULL
virions	NULL
.	NULL

As	NULL
few	NULL
infected	NULL
,	NULL
activated	NULL
CD4	NULL
*	NULL
cells	NULL
appear	NULL
to	NULL
return	NULL
to	NULL
the	NULL
resting	NULL
state	NULL
(	NULL
6	NULL
)	NULL
,	NULL
little	NULL
attention	NULL
has	NULL
been	NULL
given	NULL
to	NULL
mechanisms	NULL
that	NULL
repress	NULL
HIV	NULL
transcription	NULL
and	NULL
possibly	NULL
allow	NULL
some	NULL
cells	NULL
to	NULL
support	NULL
stable	NULL
,	NULL
unproductive	NULL
infection	NULL
.	NULL

However	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
proviral	NULL
expression	NULL
within	NULL
this	NULL
reservoir	NULL
of	NULL
infected	NULL
CD4	NULL
*	NULL
cells	NULL
may	NULL
assume	NULL
greater	NULL
relevance	NULL
as	NULL
potent	NULL
combination	NULL
antiretroviral	NULL
therapies	NULL
deplete	NULL
HIV	NULL
from	NULL
productively	NULL
infected	NULL
cell	NULL
popula-tions	NULL
.	NULL

YY1	NULL
is	NULL
a	NULL
widely	NULL
distributed	NULL
68-kDa	NULL
multifunctional	NULL
transcription	NULL
factor	NULL
that	NULL
directly	NULL
interacts	NULL
with	NULL
many	NULL
viral	NULL
and	NULL
cellular	NULL
nuclear	NULL
factors	NULL
(	NULL
5	NULL
,	NULL
15	NULL
,	NULL
24	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
demonstrated	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
that	NULL
a	NULL
protein	NULL
complex	NULL
present	NULL
in	NULL
HeLa	NULL
nuclear	NULL
extract	NULL
binds	NULL
the	NULL
HIV-1	NULL
LTR	NULL
initiation	NULL
region	NULL
(	NULL
-17	NULL
to	NULL
+27	NULL
)	NULL
and	NULL
that	NULL
this	NULL
complex	NULL
is	NULL
specifically	NULL
depleted	NULL
by	NULL
anti-	NULL
YY1	NULL
monoclonal	NULL
antibod-ies	NULL
.	NULL

Moreover	NULL
,	NULL
we	NULL
found	NULL
that	NULL
expression	NULL
of	NULL
YY1	NULL
inhibited	NULL
HIV-1	NULL
LTR	NULL
transcription	NULL
and	NULL
virion	NULL
production	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
of	NULL
the	NULL
YYl-containing	NULL
LTR-binding	NULL
complex	NULL
suggested	NULL
that	NULL
this	NULL
might	NULL
be	NULL
a	NULL
multiprotein	NULL
complex	NULL
.	NULL

Biochemical	NULL
studies	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
second	NULL
factor	NULL
that	NULL
proved	NULL
to	NULL
cooperate	NULL
in	NULL
function	NULL
with	NULL
YY1	NULL
.	NULL

Three	NULL
other	NULL
factors	NULL
,	NULL
USF	NULL
(	NULL
8	NULL
)	NULL
,	NULL
LSF	NULL
(	NULL
also	NULL
known	NULL
as	NULL
LBP-1	NULL
,	NULL
UBP-1	NULL
,	NULL
and	NULL
CP-2	NULL
[	NULL
9	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
29	NULL
]	NULL
)	NULL
,	NULL
and	NULL
TDP-43	NULL
(	NULL
19	NULL
)	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
HIV-1	NULL
LTR	NULL
within	NULL
the	NULL
-17	NULL
to	NULL
+27	NULL
region	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Institute	NULL
of	NULL
Human	NULL
Virology	NULL
,	NULL
MBRF	NULL
N552	NULL
,	NULL
725	NULL
W.	NULL
Lombard	NULL
St.	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21201	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
410	NULL
)	NULL
706-4607	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
410	NULL
)	NULL
706-1992	NULL
.	NULL

E-mail	NULL
:	NULL
margolis	NULL
@	NULL
umbi	NULL
umd.edu	NULL
.	NULL

9375	NULL
that	NULL
is	NULL
also	NULL
recognized	NULL
by	NULL
YY1	NULL
.	NULL

LSF	NULL
(	NULL
LBP-1/UBP/CP-2	NULL
)	NULL
is	NULL
a	NULL
ubiquitous	NULL
factor	NULL
demonstrated	NULL
to	NULL
directly	NULL
inhibit	NULL
HIV	NULL
transcription	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
16	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Paradoxically	NULL
,	NULL
while	NULL
LSF	NULL
can	NULL
repress	NULL
HIV	NULL
transcription	NULL
in	NULL
vitro	NULL
(	NULL
14	NULL
)	NULL
,	NULL
transient	NULL
expression	NULL
of	NULL
LSF	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
in	NULL
vivo	NULL
activity	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
16	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
function	NULL
of	NULL
TDP-43	NULL
is	NULL
unknown	NULL
,	NULL
while	NULL
USF	NULL
acts	NULL
as	NULL
an	NULL
activator	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
8	NULL
,	NULL
19	NULL
)	NULL
.	NULL

We	NULL
find	NULL
that	NULL
the	NULL
protein	NULL
complex	NULL
that	NULL
recognizes	NULL
the	NULL
HIV-1	NULL
LTR	NULL
initiation	NULL
region	NULL
contains	NULL
a	NULL
second	NULL
factor	NULL
in	NULL
addition	NULL
to	NULL
YY1	NULL
.	NULL

Further	NULL
,	NULL
YY1	NULL
cooperates	NULL
with	NULL
this	NULL
factor	NULL
in	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
and	NULL
virus	NULL
production	NULL
.	NULL

This	NULL
unique	NULL
interaction	NULL
may	NULL
allow	NULL
for	NULL
selective	NULL
repression	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
and	NULL
could	NULL
allow	NULL
some	NULL
cells	NULL
to	NULL
establish	NULL
stable	NULL
,	NULL
nonproductive	NULL
infection	NULL
.	NULL

The	NULL
discovery	NULL
of	NULL
a	NULL
selective	NULL
mechanism	NULL
of	NULL
transcriptional	NULL
repression	NULL
may	NULL
lead	NULL
to	NULL
targeted	NULL
approaches	NULL
to	NULL
inhibiting	NULL
HIV	NULL
gene	NULL
expression	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Nuclear	NULL
extracts	NULL
.	NULL

Large-scale	NULL
preparation	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
CEM	NULL
cells	NULL
for	NULL
chromatographic	NULL
purification	NULL
of	NULL
the	NULL
repressor	NULL
complex	NULL
sequence	NULL
(	NULL
RCS	NULL
)	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
7	NULL
)	NULL
with	NULL
the	NULL
following	NULL
minor	NULL
modifications	NULL
:	NULL
buffers	NULL
A	NULL
and	NULL
C	NULL
were	NULL
supplemented	NULL
with	NULL
1	NULL
mM	NULL
NaF	NULL
,	NULL
1	NULL
mM	NULL
Na	NULL
;	NULL
VO4	NULL
,	NULL
10	NULL
mg	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
1	NULL
pg	NULL
of	NULL
pepstatin	NULL
A	NULL
per	NULL
ml	NULL
.	NULL

Chymostatin	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
was	NULL
also	NULL
added	NULL
to	NULL
buffer	NULL
A	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
B-glycerolphos-phate	NULL
was	NULL
added	NULL
to	NULL
buffer	NULL
C.	NULL
EMSA	NULL
.	NULL

The	NULL
double	NULL
stranded	NULL
oligonucleotides	NULL
used	NULL
in	NULL
this	NULL
study	NULL
were	NULL
LTR	NULL
(	NULL
corresponding	NULL
to	NULL
the	NULL
-17	NULL
to	NULL
+27	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
)	NULL
;	NULL
RCS	NULL
(	NULL
-10	NULL
to	NULL
+27	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
)	NULL
;	NULL
mRCS	NULL
(	NULL
-10	NULL
to	NULL
+27	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
)	NULL
,	NULL
carrying	NULL
three	NULL
mutations	NULL
at	NULL
positions	NULL
-1/+1	NULL
(	NULL
5-GG-3'-5	NULL
``	NULL
-CC-3	NULL
'	NULL
)	NULL
,	NULL
+10/+11	NULL
(	NULL
5'-GG-3'-5'-TC-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
+17/+18	NULL
(	NULL
5'-CC-3'-5'-GG-3	NULL
'	NULL
)	NULL
;	NULL
and	NULL
P5	NULL
,	NULL
carrying	NULL
a	NULL
canonical	NULL
binding	NULL
site	NULL
for	NULL
YY1	NULL
from	NULL
the	NULL
-60	NULL
region	NULL
of	NULL
the	NULL
adeno-associated	NULL
virus	NULL
(	NULL
AAV	NULL
)	NULL
P5	NULL
promoter	NULL
(	NULL
24	NULL
)	NULL
.	NULL

All	NULL
oligonucleotides	NULL
were	NULL
end	NULL
labeled	NULL
with	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

and	NULL
[	NULL
y-*PJATP	NULL
.	NULL

Purified	NULL
oligonucleotide	NULL
probe	NULL
(	NULL
2	NULL
X	NULL
10	NULL
%	NULL
cpm	NULL
)	NULL
and	NULL
4	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
or	NULL
0.2	NULL
pl	NULL
of	NULL
affinity	NULL
chromatography	NULL
fraction	NULL
were	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
12	NULL
%	NULL
glycerol	NULL
,	NULL
12	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
60	NULL
mM	NULL
KCI	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
4	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.6	NULL
mM	NULL
EDTA	NULL
,	NULL
0.6	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
and	NULL
10	NULL
wM	NULL
zinc	NULL
acetate	NULL
(	NULL
final	NULL
volume	NULL
,	NULL
20	NULL
wl	NULL
)	NULL
.	NULL

Two	NULL
micrograms	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
was	NULL
added	NULL
to	NULL
reaction	NULL
mixtures	NULL
containing	NULL
nuclear	NULL
extract	NULL
;	NULL
100	NULL
ng	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
50	NULL
ug	NULL
of	NULL
bovine	NULL
serum	NULL
albumin	NULL
were	NULL
added	NULL
to	NULL
binding	NULL
reaction	NULL
mixtures	NULL
with	NULL
purified	NULL
fractions	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenaturing	NULL
polyacrylamide	NULL
gel	NULL
9376	NULL
ROMERIO	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

CYY1	NULL
Mab	NULL
+	NULL
+	NULL
OEL1A	NULL
MAb	NULL
+	NULL
aIgG-Agarose	NULL
+	NULL
+	NULL
+	NULL
+	NULL
CEM	NULL
-	NULL
NE	NULL
U937	NULL
NE	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
<	NULL
4	NULL
--	NULL
-	NULL
supershift	NULL
a	NULL
YY1-specific	NULL
complex	NULL
Le	NULL
8	NULL
9	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

YY1	NULL
LTR-binding	NULL
activity	NULL
in	NULL
CEM	NULL
lymphocytes	NULL
and	NULL
U937	NULL
monocytoid	NULL
cells	NULL
.	NULL

The	NULL
LTR	NULL
(	NULL
-17	NULL
to	NULL
+27	NULL
)	NULL
probe	NULL
was	NULL
incubated	NULL
with	NULL
CEM	NULL
or	NULL
U937	NULL
nuclear	NULL
extract	NULL
.	NULL

The	NULL
YY1-specific	NULL
DNA-protein	NULL
complex	NULL
was	NULL
depleted	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
anti-YY1	NULL
monoclonal	NULL
antibody	NULL
(	NULL
«	NULL
YY1	NULL
MAb	NULL
)	NULL
and	NULL
anti-IgG	NULL
agarose	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
control	NULL
antibody	NULL
(	NULL
anti-E1A	NULL
)	NULL
and	NULL
anti-IgG	NULL
agarose	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
9	NULL
)	NULL
or	NULL
anti-IgG	NULL
agarose	NULL
alone	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
7	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

(	NULL
20:1	NULL
)	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
12.5	NULL
mM	NULL
Tris-borate	NULL
and	NULL
0.05	NULL
mM	NULL
EDTA	NULL
.	NULL

Competition	NULL
EMSA	NULL
was	NULL
performed	NULL
with	NULL
unlabeled	NULL
RCS	NULL
,	NULL
mRCS	NULL
,	NULL
or	NULL
P5	NULL
oligonucleotide	NULL
in	NULL
the	NULL
indicated	NULL
amount	NULL
.	NULL

For	NULL
experiments	NULL
using	NULL
crude	NULL
nuclear	NULL
extract	NULL
,	NULL
anti-	NULL
YY1	NULL
monoclonal	NULL
antibody	NULL
or	NULL
control	NULL
monoclonal	NULL
antibody	NULL
(	NULL
anti-E1A	NULL
,	NULL
a	NULL
gift	NULL
of	NULL
Y.	NULL
Shi	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
EMSA	NULL
reaction	NULL
mixture	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
antibody-protein-DNA	NULL
complexes	NULL
were	NULL
depleted	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
3	NULL
ul	NULL
of	NULL
anti-immunoglobulin	NULL
G	NULL
(	NULL
IgG	NULL
)	NULL
agarose	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

,	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
and	NULL
centrifugation	NULL
at	NULL
2,500	NULL
x	NULL
g	NULL
for	NULL
5	NULL
minutes	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
recovered	NULL
and	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenaturing	NULL
gel	NULL
.	NULL

For	NULL
antibody	NULL
interference	NULL
EMSA	NULL
with	NULL
nuclear	NULL
extract	NULL
fractions	NULL
,	NULL
3	NULL
mg	NULL
of	NULL
purified	NULL
anti-YY1	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
,	NULL
an	NULL
equivalent	NULL
amount	NULL
of	NULL
rabbit	NULL
IgG	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
1	NULL
pl	NULL
of	NULL
anti-LSF	NULL
rabbit	NULL
antiserum	NULL
,	NULL
or	NULL
1	NULL
pl	NULL
of	NULL
preimmune	NULL
rabbit	NULL
serum	NULL
was	NULL
added	NULL
and	NULL
the	NULL
EMSA	NULL
reaction	NULL
mixtures	NULL
were	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Phosphatase	NULL
experiments	NULL
.	NULL

For	NULL
phosphatase	NULL
experiments	NULL
,	NULL
EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
above	NULL
,	NULL
but	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1.0	NULL
U	NULL
of	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
Biochemicals	NULL
,	NULL
Indianapolis	NULL
,	NULL
Ind	NULL
.	NULL
)	NULL

.	NULL

Where	NULL
indicated	NULL
,	NULL
10	NULL
mM	NULL
NaF	NULL
was	NULL
added	NULL
to	NULL
inhibit	NULL
phosphatase	NULL
activity	NULL
.	NULL

The	NULL
reaction	NULL
mixtures	NULL
were	NULL
then	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
with	NULL
DNA	NULL
probe	NULL
and	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
acrylamide	NULL
gel	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Ion-exchange	NULL
chromatography	NULL
.	NULL

Activated	NULL
P11	NULL
phosphocellulose	NULL
(	NULL
Whatman	NULL
,	NULL
Clifton	NULL
,	NULL
N.J.	NULL
)	NULL
was	NULL
equilibrated	NULL
with	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
and	NULL
0.5	NULL
mM	NULL
DTT	NULL
.	NULL

CEM	NULL
cell	NULL
nuclear	NULL
extract	NULL
was	NULL
loaded	NULL
at	NULL
0.4	NULL
ml/min	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
eluted	NULL
in	NULL
a	NULL
linear	NULL
gradient	NULL
of	NULL
50	NULL
mM	NULL
to	NULL
1	NULL
M	NULL
NaCl	NULL
.	NULL

Fractions	NULL
shown	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-YY1	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
to	NULL
contain	NULL
YY1	NULL
and	NULL
by	NULL
EMSA	NULL
to	NULL
contain	NULL
RCS-binding	NULL
activity	NULL
were	NULL
pooled	NULL
and	NULL
dialyzed	NULL
against	NULL
a	NULL
solution	NULL
containing	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
NaCl	NULL
before	NULL
DEAE-cellulose	NULL
chromatography	NULL
.	NULL

A	NULL
DEAE-cellulose	NULL
DE5S2	NULL
column	NULL
(	NULL
Whatman	NULL
)	NULL
was	NULL
loaded	NULL
with	NULL
pooled	NULL
fractions	NULL
at	NULL
0.2	NULL
ml/min	NULL
.	NULL

The	NULL
column	NULL
was	NULL
washed	NULL
and	NULL
eluted	NULL
,	NULL
and	NULL
the	NULL
fractions	NULL
were	NULL
analyzed	NULL
as	NULL
above	NULL
.	NULL

Fractions	NULL
positive	NULL
by	NULL
both	NULL
Western	NULL
blot	NULL
and	NULL
gel	NULL
shift	NULL
analysis	NULL
were	NULL
subjected	NULL
to	NULL
further	NULL
purification	NULL
by	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
.	NULL

DNA	NULL
affinity	NULL
chromatography	NULL
.	NULL

A	NULL
double-stranded	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
region	NULL
-10	NULL
to	NULL
+27	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
was	NULL
ligated	NULL
and	NULL
coupled	NULL
to	NULL
CNBr-	NULL
activated	NULL
Sepharose	NULL
CL-4B	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Active	NULL
fractions	NULL
from	NULL
DEAE-cellulose	NULL
chromatography	NULL
were	NULL
equilibrated	NULL
in	NULL
buffer	NULL
Z	NULL
(	NULL
25	NULL
mM	NULL
HEPES	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
,	NULL
0.1	NULL
M	NULL
NaCl	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
12.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
.	NULL

Affinity	NULL
resin	NULL
was	NULL
washed	NULL
extensively	NULL
with	NULL
buffer	NULL
Z	NULL
without	NULL
glycerol	NULL
and	NULL
Nonidet	NULL
P-40	NULL
.	NULL

Fractions	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
10	NULL
ag	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
loaded	NULL
by	NULL
gravity	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
eluted	NULL
with	NULL
a	NULL
step	NULL
gradient	NULL
of	NULL
0.1	NULL
to	NULL
1	NULL
M	NULL
NaCl	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
,	NULL
transfections	NULL
,	NULL
and	NULL
assays	NULL
.	NULL

CEM	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
transfected	NULL
as	NULL
follows	NULL
.	NULL

Twenty	NULL
micrograms	NULL
of	NULL
plasmid	NULL
DNA	NULL
was	NULL
prepared	NULL
in	NULL
430	NULL
pl	NULL
of	NULL
distilled	NULL
water	NULL
;	NULL
60	NULL
pl	NULL
of	NULL
a	NULL
1	NULL
M	NULL
CaC	NULL
]	NULL
;	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
the	NULL
DNA	NULL
.	NULL

Five	NULL
hundred	NULL
microliters	NULL
of	NULL
2	NULL
%	NULL
HBS	NULL
solution	NULL
(	NULL
1	NULL
%	NULL
HEPES	NULL
,	NULL
1.6	NULL
%	NULL
NaCl	NULL
[	NULL
pH	NULL
7.08	NULL
]	NULL
)	NULL
and	NULL
10	NULL
pl	NULL
of	NULL
100	NULL
%	NULL
PO	NULL
,	NULL
solution	NULL
(	NULL
483	NULL
mg	NULL
of	NULL
Na	NULL
;	NULL
HPO	NULL
,	NULL
and	NULL
497	NULL
mg	NULL
of	NULL
NaH	NULL
;	NULL
PO	NULL
,	NULL
in	NULL
100	NULL
ml	NULL
of	NULL
distilled	NULL
water	NULL
)	NULL
were	NULL
premixed	NULL
and	NULL
then	NULL
added	NULL
to	NULL
the	NULL
DNA-CaCl	NULL
;	NULL
mixture	NULL
.	NULL

After	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
solution	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
(	NULL
2.5	NULL
x	NULL
10°	NULL
to	NULL
4	NULL
X	NULL
10°	NULL
cells/plate	NULL
)	NULL
.	NULL

Twelve	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
and	NULL
fed	NULL
fresh	NULL
medium	NULL
.	NULL

Forty-cight	NULL
hours	NULL
later	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
cellular	NULL
extracts	NULL
were	NULL
prepared	NULL
,	NULL
and	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
and	NULL
B-galactosidase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
2	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
,	NULL
but	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
200	NULL
pl	NULL
of	NULL
lysis	NULL
buffer	NULL
and	NULL
three	NULL
freeze-thaw	NULL
steps	NULL
were	NULL
performed	NULL
.	NULL

Five	NULL
micrograms	NULL
of	NULL
cellular	NULL
extract	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
10	NULL
pl	NULL
was	NULL
used	NULL
for	NULL
luciferase	NULL
reactions	NULL
.	NULL

To	NULL
measure	NULL
transfection	NULL
efficiency	NULL
and	NULL
effects	NULL
on	NULL
other	NULL
promoters	NULL
,	NULL
cellular	NULL
extract	NULL
was	NULL
tested	NULL
for	NULL
B-galactosidase	NULL
or	NULL
luciferase	NULL
activity	NULL
.	NULL

CAT	NULL
assays	NULL
were	NULL
then	NULL
normalized	NULL
for	NULL
B-galactosidase	NULL
or	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
control	NULL
reporter	NULL
constructs	NULL
pCH110	NULL
,	NULL
expressing	NULL
B-galactosidase	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
)	NULL
,	NULL
and	NULL
pHB-ac-tin-luciferase	NULL
(	NULL
26	NULL
)	NULL
,	NULL
were	NULL
used	NULL
in	NULL
cotransfection	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
aliquots	NULL
of	NULL
culture	NULL
medium	NULL
were	NULL
sampled	NULL
for	NULL
detection	NULL
of	NULL
HIV-1	NULL
p24***	NULL
protein	NULL
by	NULL
antigen	NULL
capture	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Coulter	NULL
Corporation	NULL
,	NULL
Hialeah	NULL
,	NULL
Fla.	NULL
)	NULL
.	NULL

ms	NULL
(	NULL
ABC	NULL
)	NULL
-CAT	NULL
construction	NULL
.	NULL

For	NULL
CAT	NULL
reporter	NULL
assays	NULL
of	NULL
HIV-1	NULL
LTR	NULL
unresponsive	NULL
to	NULL
YY1	NULL
and	NULL
LSF	NULL
,	NULL
a	NULL
CAT	NULL
gene	NULL
was	NULL
cloned	NULL
into	NULL
plasmid	NULL
ms	NULL
(	NULL
ABC	NULL
)	NULL
'	NULL
.	NULL

This	NULL
construct	NULL
contains	NULL
mutations	NULL
that	NULL
abolish	NULL
LSF	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
promoter	NULL
(	NULL
12	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
six	NULL
compensatory	NULL
mutations	NULL
that	NULL
maintain	NULL
the	NULL
folding	NULL
of	NULL
the	NULL
TAR	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
Probe	NULL
RCS	NULL
Competitor	NULL
RCS	NULL
mRCS	NULL
(	NULL
molar	NULL
-	NULL
excess	NULL
)	NULL
10	NULL
50	NULL
100	NULL
10	NULL
50	NULL
100	NULL
INHIBITION	NULL
OF	NULL
HIV-1	NULL
BY	NULL
YYI	NULL
AND	NULL
LSF	NULL
-	NULL
9377	NULL
mRCS	NULL
-	NULL
P5	NULL
PS5	NULL
10	NULL
50	NULL
100	NULL
«	NULL
<	NULL
«	NULL
l	NULL
--	NULL
-	NULL
_	NULL
RCS	NULL
-	NULL
complex	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
8	NULL
9	NULL
10	NULL
1	NULL
12	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

A	NULL
mutated	NULL
RCS	NULL
probe	NULL
and	NULL
a	NULL
high-affinity	NULL
YY1	NULL
binding	NULL
sequence	NULL
do	NULL
not	NULL
compete	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
YY1-specific	NULL
complex	NULL
on	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

When	NULL
used	NULL
in	NULL
EMSA	NULL
,	NULL
an	NULL
mRCS	NULL
probe	NULL
carrying	NULL
three	NULL
mutations	NULL
described	NULL
to	NULL
prevent	NULL
the	NULL
binding	NULL
of	NULL
LSF	NULL
to	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
12	NULL
)	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
formation	NULL
of	NULL
the	NULL
YY1-specific	NULL
complex	NULL
(	NULL
lane	NULL
11	NULL
)	NULL
.	NULL

In	NULL
competition	NULL
experiments	NULL
,	NULL
this	NULL
oligonucleotide	NULL
failed	NULL
to	NULL
compete	NULL
with	NULL
the	NULL
RCS	NULL
probe	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
RCS	NULL
complex	NULL
.	NULL

The	NULL
P5	NULL
oligonucleotide	NULL
encoding	NULL
the	NULL
canonical	NULL
YY1	NULL
binding	NULL
site	NULL
present	NULL
at	NULL
position	NULL
-60	NULL
of	NULL
the	NULL
AAV	NULL
P5	NULL
promoter	NULL
(	NULL
24	NULL
)	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
YY1-specific	NULL
complex	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
smaller	NULL
arrow	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
when	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
this	NULL
oligonucleotide	NULL
was	NULL
unable	NULL
to	NULL
inhibit	NULL
formation	NULL
of	NULL
the	NULL
YY1-specific	NULL
complex	NULL
with	NULL
the	NULL
RCS	NULL
probe	NULL
(	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
)	NULL
.	NULL

stem-loop	NULL
structure	NULL
and	NULL
response	NULL
to	NULL
Tat	NULL
activation	NULL
(	NULL
23	NULL
)	NULL
.	NULL

BamHI	NULL
sites	NULL
were	NULL
created	NULL
flanking	NULL
a	NULL
CAT	NULL
gene	NULL
by	NULL
PCR	NULL
amplification	NULL
.	NULL

The	NULL
CAT	NULL
gene	NULL
was	NULL
then	NULL
inserted	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
(	NULL
+82	NULL
)	NULL
of	NULL
ms	NULL
(	NULL
ABC	NULL
)	NULL
'	NULL
,	NULL
and	NULL
the	NULL
promoter	NULL
and	NULL
reporter	NULL
sequences	NULL
were	NULL
confirmed	NULL
.	NULL

RESULTS	NULL
YY1-specific	NULL
LTR-binding	NULL
activity	NULL
in	NULL
lymphocyte	NULL
and	NULL
mono-cyte	NULL
cell	NULL
lines	NULL
.	NULL

EMSAs	NULL
using	NULL
a	NULL
-17	NULL
to	NULL
+27	NULL
oligonucleotide	NULL
and	NULL
nuclear	NULL
extract	NULL
from	NULL
the	NULL
CD4*	NULL
lymphocyte	NULL
cell	NULL
line	NULL
CEM	NULL
or	NULL
the	NULL
monocytoid	NULL
cell	NULL
line	NULL
U937	NULL
revealed	NULL
several	NULL
DNA-protein	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
the	NULL
anti-	NULL
YY1	NULL
monoclonal	NULL
antibody	NULL
1G3	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Y.	NULL
Shi	NULL
)	NULL
specifically	NULL
depleted	NULL
the	NULL
lowest-mobility	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
8	NULL
)	NULL
.	NULL

A	NULL
control	NULL
antibody	NULL
(	NULL
anti-E1A	NULL
,	NULL
a	NULL
gift	NULL
of	NULL
Y.	NULL
Shi	NULL
)	NULL
or	NULL
an	NULL
agarose-conjugated	NULL
anti-IgG	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
5	NULL
,	NULL
7	NULL
,	NULL
and	NULL
9	NULL
)	NULL
.	NULL

For	NULL
these	NULL
studies	NULL
we	NULL
modified	NULL
the	NULL
protocol	NULL
used	NULL
to	NULL
prepare	NULL
nuclear	NULL
extracts	NULL
to	NULL
minimize	NULL
protein	NULL
degradation	NULL
and	NULL
dephosphorylation	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
using	NULL
HeLa	NULL
nuclear	NULL
extract	NULL
prepared	NULL
from	NULL
large	NULL
batches	NULL
of	NULL
cultured	NULL
cells	NULL
detected	NULL
two	NULL
YY1-specific	NULL
complexes	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
detected	NULL
only	NULL
one	NULL
YY1-specific	NULL
complex	NULL
in	NULL
nuclear	NULL
extracts	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
protocol	NULL
from	NULL
smaller	NULL
culture	NULL
volumes	NULL
of	NULL
the	NULL
lymphoid	NULL
cell	NULL
lines	NULL
CEM	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
A3.01	NULL
,	NULL
the	NULL
monocytoid	NULL
cell	NULL
line	NULL
U937	NULL
,	NULL
and	NULL
primary	NULL
lymphocyte	NULL
cell	NULL
populations	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
tried	NULL
to	NULL
further	NULL
delimit	NULL
the	NULL
sequence	NULL
necessary	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
LTR-binding	NULL
complex	NULL
that	NULL
contains	NULL
YY1	NULL
.	NULL

EMSAs	NULL
using	NULL
a	NULL
-10	NULL
to	NULL
+27	NULL
oligonucleotide	NULL
and	NULL
crude	NULL
or	NULL
1.0u	NULL
CIP	NULL
__	NULL
-	NULL
+	NULL
+	NULL
=	NULL
10mM	NULL
NaF	NULL
-	NULL
-	NULL
+	NULL
+	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

YY1-LSF	NULL
complex	NULL
formation	NULL
is	NULL
inhibited	NULL
by	NULL
phosphatase	NULL
.	NULL

CEM	NULL
nuclear	NULL
extracts	NULL
were	NULL
treated	NULL
with	NULL
calf	NULL
intestinal	NULL
phosphatase	NULL
(	NULL
CIP	NULL
)	NULL
,	NULL
the	NULL
phosphatase	NULL
inhibitor	NULL
NaF	NULL
,	NULL
or	NULL
both	NULL
and	NULL
then	NULL
used	NULL
in	NULL
EMSA	NULL
with	NULL
the	NULL
LTR	NULL
probe	NULL
.	NULL

Treatment	NULL
with	NULL
CIP	NULL
abolished	NULL
formation	NULL
of	NULL
the	NULL
YY1-LTR	NULL
complex	NULL
,	NULL
indicated	NULL
by	NULL
the	NULL
arrow	NULL
;	NULL
this	NULL
effect	NULL
was	NULL
inhibited	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
NaF	NULL
.	NULL

9378	NULL
ROMERIO	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

A	NULL
NEs	NULL
PHOSPHOCELLULOSE	NULL
COLUMN	NULL
FRACTIONS	NULL
MWM	NULL
14	NULL
15	NULL
1	NULL
6	NULL
17	NULL
18	NULL
19	NULL
2	NULL
0	NULL
21	NULL
22	NULL
23	NULL
2	NULL
4	NULL
83	NULL
--	NULL
-	NULL
I	NULL
I	NULL
-	NULL
¥y1i	NULL
ha	NULL
+-	NULL
yey	NULL
=	NULL
47.5	NULL
--	NULL
YY1-SPECIFIC	NULL
b	NULL
‘	NULL
’	NULL
1k	NULL
COMPLEX	NULL
6	NULL
£	NULL
B	NULL
NEs	NULL
DEAE-CELLULOSE	NULL
COLUMN	NULL
FRACTIONS	NULL
MWM	NULL
9	NULL
10	NULL
ii	NULL
ira	NULL
is	NULL
i4	NULL
is	NULL
i6	NULL
i7	NULL
83	NULL
--	NULL
¥¥i	NULL
«	NULL
--	NULL
-	NULL
a	NULL
»	NULL
TD	NULL
UGB	NULL
GB	NULL
GiB	NULL
-	NULL
»	NULL
as	NULL
cm	NULL
as	NULL
<	NULL
4	NULL
-__-62	NULL
--	NULL
47.5	NULL
--	NULL
YY1-SPECIFIC	NULL
COMPLEX	NULL
vea	NULL
-	NULL
wen	NULL
tone	NULL
tah	NULL
bath	NULL
tort	NULL
st	NULL
>	NULL
C	NULL
NEs	NULL
DNA-AFFINITY	NULL
FRACTIONS	NULL
MWM	NULL
0.2	NULL
0.3	NULL
0.4	NULL
0.5	NULL
0.6	NULL
0.7	NULL
0.8	NULL
0.9	NULL
M	NULL
NaCl	NULL
83	NULL
-	NULL
6	NULL
ad	NULL
<	NULL
c	NULL
«	NULL
lb	NULL
GB	NULL
|	NULL
oo	NULL
«	NULL
G	NULL
--	NULL
-62	NULL
47.5	NULL
--	NULL
w	NULL
‘	NULL
k	NULL
``	NULL
|	NULL
l	NULL
G	NULL
_	NULL
\	NULL
h-	NULL
Ol	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Copurification	NULL
of	NULL
RCS-binding	NULL
activity	NULL
and	NULL
YY1	NULL
.	NULL

Western	NULL
blotting	NULL
(	NULL
upper	NULL
panels	NULL
)	NULL
used	NULL
rabbit	NULL
polyclonal	NULL
anti-¥Y1	NULL
C-20	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
,	NULL
and	NULL
EMSA	NULL
(	NULL
lower	NULL
panels	NULL
)	NULL
used	NULL
the	NULL
RCS	NULL
probe	NULL
.	NULL

Western	NULL
blotting	NULL
was	NULL
performed	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
and	NULL
5	NULL
pg	NULL
of	NULL
phosphocellulose	NULL
(	NULL
A	NULL
)	NULL
,	NULL
2.5	NULL
mg	NULL
of	NULL
DEAE-cellulose	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
200	NULL
ng	NULL
of	NULL
DNA	NULL
affinity	NULL
column	NULL
eluate	NULL
(	NULL
C	NULL
)	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
with	NULL
4	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
and	NULL
1	NULL
jg	NULL
of	NULL
phosphocellulose	NULL
(	NULL
A	NULL
)	NULL
,	NULL
500	NULL
ng	NULL
of	NULL
DEAE-cellulose	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
20	NULL
ng	NULL
of	NULL
DNA	NULL
affinity	NULL
column	NULL
eluate	NULL
(	NULL
C	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
YY1-specific	NULL
complexes	NULL
as	NULL
validated	NULL
by	NULL
anti-YY1	NULL
interference	NULL
in	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
(	NULL
MWM	NULL
)	NULL
are	NULL
indicated	NULL
,	NULL
in	NULL
thousands	NULL
.	NULL

Values	NULL
at	NULL
the	NULL
top	NULL
of	NULL
each	NULL
panel	NULL
are	NULL
molar	NULL
concentrations	NULL
of	NULL
NaCl	NULL
.	NULL

NEs	NULL
,	NULL
unfractionated	NULL
nuclear	NULL
extract	NULL
.	NULL

YY1-SPECIFIC	NULL
COMPLEX	NULL
partially	NULL
purified	NULL
nuclear	NULL
extract	NULL
fractions	NULL
from	NULL
the	NULL
CD4	NULL
*	NULL
T-lymphocyte	NULL
cell	NULL
line	NULL
CEM	NULL
(	NULL
see	NULL
below	NULL
)	NULL
revealed	NULL
only	NULL
one	NULL
retarded	NULL
band	NULL
,	NULL
which	NULL
contains	NULL
YY1	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
anti-	NULL
Y	NULL
Y1	NULL
antibodies	NULL
to	NULL
specifically	NULL
abrogate	NULL
its	NULL
formation	NULL
.	NULL

Fur	NULL
ther	NULL
deletion	NULL
of	NULL
residues	NULL
from	NULL
either	NULL
the	NULL
5	NULL
or	NULL
3	NULL
'	NULL
end	NULL
of	NULL
this	NULL
oligonucleotide	NULL
greatly	NULL
reduced	NULL
the	NULL
formation	NULL
of	NULL
this	NULL
EMSA	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Hereafter	NULL
we	NULL
refer	NULL
to	NULL
this	NULL
sequence	NULL
as	NULL
RCS	NULL
(	NULL
for	NULL
repressor	NULL
complex	NULL
sequence	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
INHIBITION	NULL
OF	NULL
HIV-1	NULL
BY	NULL
YYI	NULL
AND	NULL
LSF	NULL
-	NULL
9379	NULL
NES	NULL
DNA-AFFINITY	NULL
FRACTIONS	NULL
MWM	NULL
0	NULL
.	NULL

2	NULL
0.3	NULL
0	NULL
.	NULL

4	NULL
178	NULL
~~	NULL
82	NULL
61	NULL
__	NULL
-s	NULL
«	NULL
-m	NULL
»	NULL
d4	NULL
a7.5-32.5	NULL
-	NULL
I	NULL
.	NULL

&	NULL
5	NULL
0	NULL
.	NULL

6	NULL
0.7	NULL
0	NULL
.	NULL

8	NULL
0	NULL
.	NULL

9	NULL
M	NULL
NaCl	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

LSF	NULL
copurifies	NULL
with	NULL
YY1	NULL
and	NULL
the	NULL
RCS-binding	NULL
activity	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
fractions	NULL
were	NULL
subjected	NULL
to	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
an	NULL
anti-CP-2	NULL
(	NULL
LSFe/LBP-1¢	NULL
;	NULL
a	NULL
gift	NULL
of	NULL
M.	NULL
Sheffery	NULL
)	NULL
antiserum	NULL
.	NULL

The	NULL
0.3	NULL
and	NULL
0.4	NULL
M	NULL
NaCl	NULL
fractions	NULL
were	NULL
found	NULL
to	NULL
contain	NULL
LSF	NULL
and	NULL
to	NULL
copurify	NULL
with	NULL
YY1	NULL
and	NULL
the	NULL
RCS-binding	NULL
activity	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
(	NULL
MWM	NULL
)	NULL
are	NULL
indicated	NULL
,	NULL
in	NULL
thousands	NULL
.	NULL

NEs	NULL
,	NULL
unfractionated	NULL
nuclear	NULL
extract	NULL
.	NULL

Another	NULL
factor	NULL
participates	NULL
in	NULL
LTR	NULL
binding	NULL
with	NULL
YY1	NULL
.	NULL

While	NULL
the	NULL
LTR-binding	NULL
complex	NULL
we	NULL
have	NULL
identified	NULL
contains	NULL
YY1	NULL
,	NULL
several	NULL
observations	NULL
suggested	NULL
that	NULL
this	NULL
complex	NULL
might	NULL
contain	NULL
additional	NULL
components	NULL
and/or	NULL
a	NULL
uniquely	NULL
modified	NULL
form	NULL
of	NULL
YY1	NULL
.	NULL

First	NULL
,	NULL
the	NULL
lymphoid	NULL
transcription	NULL
factor	NULL
LSF	NULL
(	NULL
LBP-1/UBP/	NULL
CP-2	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
recognize	NULL
the	NULL
same	NULL
LTR	NULL
sequence	NULL
as	NULL
YY1	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
16	NULL
,	NULL
28	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
a	NULL
triple	NULL
mutant	NULL
of	NULL
the	NULL
-10/+27	NULL
RCS	NULL
probe	NULL
very	NULL
similar	NULL
to	NULL
a	NULL
triple	NULL
mutant	NULL
that	NULL
disrupts	NULL
LSF	NULL
binding	NULL
at	NULL
this	NULL
site	NULL
(	NULL
12	NULL
)	NULL
was	NULL
not	NULL
able	NULL
to	NULL
form	NULL
YY1-specific	NULL
complexes	NULL
or	NULL
compete	NULL
for	NULL
their	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
5	NULL
to	NULL
7	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
an	NULL
oligonucleotide	NULL
encoding	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
YY1	NULL
from	NULL
the	NULL
AAV	NULL
P5	NULL
promoter	NULL
,	NULL
a	NULL
sequence	NULL
that	NULL
efficiently	NULL
binds	NULL
YY1	NULL
(	NULL
24	NULL
)	NULL
,	NULL
did	NULL
not	NULL
compete	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
YY1-specific	NULL
complex	NULL
with	NULL
the	NULL
RCS	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lanes	NULL
8	NULL
to	NULL
10	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
YY1	NULL
binds	NULL
the	NULL
HIV-1	NULL
LTR	NULL
with	NULL
cofactors	NULL
or	NULL
is	NULL
modified	NULL
in	NULL
a	NULL
way	NULL
that	NULL
makes	NULL
it	NULL
unavailable	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
P5	NULL
probe	NULL
.	NULL

Further	NULL
,	NULL
while	NULL
purified	NULL
LSF	NULL
can	NULL
repress	NULL
LTR	NULL
transcription	NULL
when	NULL
tested	NULL
in	NULL
vitro	NULL
(	NULL
14	NULL
)	NULL
,	NULL
transfection	NULL
of	NULL
LSF	NULL
expression	NULL
constructs	NULL
failed	NULL
to	NULL
inhibit	NULL
transcription	NULL
in	NULL
vivo	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
LSF	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
modulate	NULL
its	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
phosphatase	NULL
treatment	NULL
of	NULL
nuclear	NULL
extract	NULL
disrupted	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
YY1-specific	NULL
LTR-binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
purified	NULL
YY1	NULL
expressed	NULL
in	NULL
E.	NULL
coli	NULL
efficiently	NULL
bound	NULL
the	NULL
P5	NULL
probe	NULL
but	NULL
did	NULL
not	NULL
bind	NULL
the	NULL
LTR	NULL
probe	NULL
in	NULL
EMSA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
cofactor	NULL
or	NULL
proper	NULL
posttranslational	NULL
modification	NULL
of	NULL
YY1	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
.	NULL

These	NULL
observations	NULL
led	NULL
us	NULL
to	NULL
hypothesize	NULL
that	NULL
LSF	NULL
and	NULL
YY1	NULL
bind	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
function	NULL
as	NULL
part	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
.	NULL

LSF	NULL
participates	NULL
in	NULL
RCS	NULL
complex	NULL
formation	NULL
.	NULL

We	NULL
sought	NULL
to	NULL
identify	NULL
other	NULL
components	NULL
of	NULL
the	NULL
YY1-specific	NULL
LTR-binding	NULL
complex	NULL
with	NULL
a	NULL
DNA	NULL
affinity	NULL
purification	NULL
strategy	NULL
.	NULL

To	NULL
delineate	NULL
components	NULL
of	NULL
the	NULL
RCS-binding	NULL
complex	NULL
,	NULL
CEM	NULL
nuclear	NULL
extract	NULL
was	NULL
serially	NULL
fractionated	NULL
by	NULL
P11	NULL
phosphocellulose	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
,	NULL
DEAE-cellulose	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
and	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
with	NULL
a	NULL
double-stranded	NULL
oligonucleotide	NULL
encoding	NULL
the	NULL
RCS	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

At	NULL
each	NULL
step	NULL
,	NULL
fractions	NULL
enriched	NULL
for	NULL
RCS-binding	NULL
activity	NULL
were	NULL
identified	NULL
by	NULL
EMSA	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
YY1	NULL
was	NULL
assayed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

YY1	NULL
and	NULL
RCS-binding	NULL
activity	NULL
copurified	NULL
in	NULL
the	NULL
0.3	NULL
and	NULL
0.4	NULL
M	NULL
NaC	NULL
fractions	NULL
of	NULL
the	NULL
final	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
step	NULL
.	NULL

RCS-binding	NULL
activity	NULL
was	NULL
enriched	NULL
approximately	NULL
10,000-fold	NULL
by	NULL
this	NULL
procedure	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
showed	NULL
that	NULL
LSF	NULL
copurified	NULL
with	NULL
YY1	NULL
and	NULL
the	NULL
RCS-binding	NULL
activity	NULL
in	NULL
the	NULL
0.3	NULL
and	NULL
0.4	NULL
M	NULL
NaC	NULL
fractions	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

TDP-43	NULL
,	NULL
another	NULL
nuclear	NULL
protein	NULL
reported	NULL
to	NULL
bind	NULL
near	NULL
the	NULL
RCS	NULL
site	NULL
(	NULL
19	NULL
)	NULL
,	NULL
was	NULL
not	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
anti-YY1	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
as	NULL
well	NULL
as	NULL
anti-LSF	NULL
antisera	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
disrupted	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
RCS	NULL
complex	NULL
,	NULL
we	NULL
concluded	NULL
that	NULL
both	NULL
YY1	NULL
and	NULL
LSF	NULL
participate	NULL
in	NULL
RCS	NULL
complex	NULL
formation	NULL
.	NULL

Total	NULL
rabbit	NULL
IgG	NULL
,	NULL
preimmune	NULL
rabbit	NULL
se-rum	NULL
,	NULL
or	NULL
irrelevant	NULL
antibodies	NULL
such	NULL
as	NULL
anti-E1A	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
RCS	NULL
complex	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
and	NULL
B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
anti-	NULL
or	NULL
anti-LSF	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
EMSA	NULL
complexes	NULL
formed	NULL
on	NULL
a	NULL
Sp1	NULL
binding	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
both	NULL
YY1	NULL
and	NULL
LSF	NULL
bind	NULL
the	NULL
HIV-1	NULL
LTR	NULL
as	NULL
part	NULL
of	NULL
a	NULL
multiprotein	NULL
complex	NULL
.	NULL

YY1	NULL
and	NULL
LSF	NULL
synergize	NULL
in	NULL
repression	NULL
of	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
.	NULL

Cooperation	NULL
in	NULL
repression	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
was	NULL
demonstrated	NULL
by	NULL
cotransfection	NULL
of	NULL
HeLa	NULL
cells	NULL
with	NULL
the	NULL
infectious	NULL
molecular	NULL
clone	NULL
pNL4-3	NULL
(	NULL
1	NULL
)	NULL
and	NULL
vectors	NULL
expressing	NULL
YY1	NULL
(	NULL
24	NULL
)	NULL
and/or	NULL
LSF	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Q.	NULL
Zhu	NULL
and	NULL
U.	NULL
Hansen	NULL
)	NULL
.	NULL

As	NULL
these	NULL
cells	NULL
support	NULL
HIV	NULL
replication	NULL
but	NULL
can	NULL
not	NULL
be	NULL
infected	NULL
,	NULL
a	NULL
measurement	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
on	NULL
a	NULL
single	NULL
round	NULL
of	NULL
viral	NULL
replication	NULL
can	NULL
be	NULL
made	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
on	NULL
viral	NULL
production	NULL
were	NULL
measured	NULL
by	NULL
testing	NULL
the	NULL
culture	NULL
supernatant	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
viral	NULL
protein	NULL
p24°*	NULL
.	NULL

In	NULL
conditions	NULL
in	NULL
which	NULL
transfection	NULL
of	NULL
a	NULL
vector	NULL
expressing	NULL
YY1	NULL
or	NULL
LSF	NULL
produced	NULL
little	NULL
inhibition	NULL
of	NULL
virion	NULL
production	NULL
,	NULL
cotransfection	NULL
of	NULL
both	NULL
factors	NULL
synergistically	NULL
inhibited	NULL
HIV	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

In	NULL
a	NULL
second	NULL
set	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effects	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
CAT	NULL
reporter	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
HIV-1	NULL
LTR	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
viral	NULL
protein	NULL
Tat	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
(	NULL
18	NULL
)	NULL
,	NULL
YY1	NULL
inhibited	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
HIV-1	NULL
LTR-driven	NULL
CAT	NULL
expression	NULL
.	NULL

We	NULL
found	NULL
little	NULL
inhibition	NULL
of	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
LTR	NULL
expression	NULL
following	NULL
cotransfection	NULL
of	NULL
LSF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
Tat-activated	NULL
,	NULL
LTR-directed	NULL
CAT	NULL
expression	NULL
was	NULL
inhibited	NULL
by	NULL
YY1	NULL
alone	NULL
and	NULL
not	NULL
significantly	NULL
affected	NULL
by	NULL
LSF	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
cotransfection	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
strongly	NULL
inhibited	NULL
CAT	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

9380	NULL
ROMERIO	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

#	NULL
f	NULL
)	NULL
?	NULL

$	NULL
4	NULL
B	NULL
06	NULL
;	NULL
y*	NULL
y	NULL
&	NULL
«	NULL
*	NULL
0°	NULL
0°	NULL
``	NULL
2	NULL
``	NULL
#	NULL
&	NULL
#	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

The	NULL
RCS-binding	NULL
complex	NULL
contains	NULL
YY1	NULL
and	NULL
LSF	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EMSA	NULL
binding	NULL
reaction	NULL
with	NULL
the	NULL
RCS	NULL
probe	NULL
(	NULL
-10/+27	NULL
)	NULL
and	NULL
5	NULL
ng	NULL
of	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
eluate	NULL
.	NULL

Complexes	NULL
were	NULL
disrupted	NULL
by	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
that	NULL
recognizes	NULL
the	NULL
carboxyl-terminal	NULL
domain	NULL
of	NULL
YY1	NULL
(	NULL
anti-YY1	NULL
[	NULL
«	NULL
YY1	NULL
]	NULL
C-20	NULL
)	NULL
or	NULL
a	NULL
polyclonal	NULL
antibody	NULL
directed	NULL
against	NULL
the	NULL
entire	NULL
molecule	NULL
(	NULL
anti-¥Y1	NULL
[	NULL
«	NULL
YY1	NULL
]	NULL
1-414	NULL
)	NULL
but	NULL
not	NULL
by	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
total	NULL
rabbit	NULL
IgG	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EMSA	NULL
binding	NULL
reaction	NULL
with	NULL
the	NULL
RCS	NULL
probe	NULL
and	NULL
5	NULL
ng	NULL
of	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
eluate	NULL
.	NULL

Complexes	NULL
were	NULL
disrupted	NULL
by	NULL
a	NULL
rabbit	NULL
antiserum	NULL
raised	NULL
against	NULL
LSF-c	NULL
(	NULL
anti-CP-2	NULL
[	NULL
«	NULL
CP2	NULL
]	NULL
)	NULL
but	NULL
not	NULL
by	NULL
preimmune	NULL
rabbit	NULL
scrum	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

In	NULL
all	NULL
of	NULL
these	NULL
experiments	NULL
,	NULL
cell	NULL
growth	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
cotransfected	NULL
simian	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
early-driven	NULL
B-galactosidase	NULL
reporter	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
B-actin	NULL
promoter-driven	NULL
luciferase	NULL
reporter	NULL
were	NULL
unaffected	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
inhibition	NULL
of	NULL
LTR-directed	NULL
CAT	NULL
expression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
was	NULL
similar	NULL
when	NULL
CAT	NULL
assay	NULL
reaction	NULL
mixtures	NULL
were	NULL
normalized	NULL
for	NULL
either	NULL
SV40	NULL
early-driven	NULL
B-galactosidase	NULL
activity	NULL
or	NULL
B-actin	NULL
promoter-driven	NULL
luciferase	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

While	NULL
LSF	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
the	NULL
SV40	NULL
late	NULL
promoter	NULL
,	NULL
it	NULL
has	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
early	NULL
promoter	NULL
(	NULL
22	NULL
)	NULL
.	NULL

As	NULL
YY1	NULL
and	NULL
LSF	NULL
do	NULL
not	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
broadly	NULL
active	NULL
viral	NULL
promoter	NULL
or	NULL
a	NULL
constitutive	NULL
cellular	NULL
promoter	NULL
,	NULL
the	NULL
cooperative	NULL
repressive	NULL
effect	NULL
of	NULL
these	NULL
factors	NULL
appears	NULL
somewhat	NULL
selective	NULL
for	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
LSF	NULL
and	NULL
YY1	NULL
can	NULL
not	NULL
be	NULL
attributed	NULL
to	NULL
general	NULL
repression	NULL
of	NULL
transcription	NULL
or	NULL
nonspe-cific	NULL
cell	NULL
toxicity	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
YY1	NULL
and	NULL
LSF	NULL
participate	NULL
in	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
RCS-binding	NULL
complex	NULL
and	NULL
cooperatively	NULL
inhibit	NULL
virion	NULL
production	NULL
by	NULL
repressing	NULL
HIV-1	NULL
transcription	NULL
.	NULL

Mutations	NULL
which	NULL
abolish	NULL
YY1	NULL
and	NULL
LSF	NULL
binding	NULL
abrograte	NULL
the	NULL
abilities	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
to	NULL
repress	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
negative	NULL
effects	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
on	NULL
HIV-1	NULL
expression	NULL
correlated	NULL
with	NULL
the	NULL
abilities	NULL
of	NULL
these	NULL
proteins	NULL
to	NULL
recognize	NULL
the	NULL
-10/+27	NULL
region	NULL
of	NULL
the	NULL
LTR	NULL
,	NULL
a	NULL
CAT	NULL
reporter	NULL
gene	NULL
was	NULL
inserted	NULL
downstream	NULL
of	NULL
the	NULL
BamHI	NULL
site	NULL
(	NULL
+82	NULL
)	NULL
of	NULL
plasmid	NULL
ms	NULL
(	NULL
ABC	NULL
)	NULL
'	NULL
.	NULL

This	NULL
construct	NULL
contains	NULL
mutations	NULL
that	NULL
abolish	NULL
LSF	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
promoter	NULL
(	NULL
12	NULL
)	NULL
as	NULL
well	NULL
as	NULL
RCS	NULL
complex	NULL
formation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

ms	NULL
(	NULL
ABC	NULL
)	NULL
'	NULL
contains	NULL
six	NULL
compensatory	NULL
mutations	NULL
that	NULL
maintain	NULL
the	NULL
folding	NULL
of	NULL
the	NULL
TAR	NULL
stem-loop	NULL
structure	NULL
and	NULL
is	NULL
defective	NULL
in	NULL
the	NULL
production	NULL
of	NULL
short	NULL
transcripts	NULL
,	NULL
but	NULL
responds	NULL
to	NULL
Tat	NULL
(	NULL
23	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
ms	NULL
(	NULL
ABC	NULL
)	NULL
'-CAT	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
was	NULL
unaffected	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
YY1	NULL
,	NULL
LSF	NULL
,	NULL
or	NULL
both	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
described	NULL
a	NULL
nuclear	NULL
protein	NULL
complex	NULL
isolated	NULL
from	NULL
CEM	NULL
lymphocytes	NULL
that	NULL
binds	NULL
the	NULL
initiator	NULL
region	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

We	NULL
have	NULL
designated	NULL
the	NULL
binding	NULL
site	NULL
RCS	NULL
(	NULL
for	NULL
repressor	NULL
complex	NULL
sequence	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
two	NULL
transcription	NULL
factors	NULL
,	NULL
YY1	NULL
and	NULL
LSF	NULL
,	NULL
are	NULL
required	NULL
for	NULL
formation	NULL
of	NULL
the	NULL
RCS-binding	NULL
complex	NULL
.	NULL

Further	NULL
,	NULL
YY1	NULL
and	NULL
LSF	NULL
cooperate	NULL
in	NULL
repres-sion	NULL
,	NULL
as	NULL
their	NULL
coexpression	NULL
synergistically	NULL
inhibits	NULL
LTR-directed	NULL
gene	NULL
expression	NULL
and	NULL
HIV-1	NULL
virion	NULL
production	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Vor	NULL
.	NULL

71	NULL
,	NULL
1997	NULL
A	NULL
soo-CMV	NULL
vector	NULL
2.5	NULL
ug	NULL
400-	NULL
``	NULL
p24	NULL
929	NULL
antigen	NULL
300-	NULL
_m-__	NULL
GMV-YY1	NULL
2.5	NULL
g	NULL
ml	NULL
--	NULL
=	NULL
(	NULL
pg/im1	NULL
)	NULL
CMV-LSF	NULL
2.5	NULL
pg	NULL
2007	NULL
1007	NULL
CMV-YY1	NULL
1.25	NULL
pg	NULL
&	NULL
CMV-LSF	NULL
1.25	NULL
ug	NULL
0	NULL
-	NULL
\	NULL
T	NULL
T	NULL
T	NULL
u	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
days	NULL
in	NULL
culture	NULL
B	NULL
35	NULL
%	NULL
35	NULL
%	NULL
13	NULL
%	NULL
5	NULL
%	NULL
tt	NULL
»	NULL
wie	NULL
=	NULL
>	NULL
pAR-Tat	NULL
25ng	NULL
+	NULL
+	NULL
+	NULL
+	NULL
pCMV	NULL
vector	NULL
(	NULL
g	NULL
)	NULL
5.0	NULL
2.5	NULL
2.5	NULL
pCMV-YY1	NULL
2.5ug	NULL
-	NULL
-	NULL
+	NULL
+	NULL
pCMV-LSF	NULL
2.5ug	NULL
-	NULL
+	NULL
-	NULL
+	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Cooperative	NULL
repression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
1.25	NULL
ug	NULL
of	NULL
HIV-1	NULL
molecular	NULL
clone	NULL
pNL4-3	NULL
and	NULL
the	NULL
indicated	NULL
amounts	NULL
of	NULL
expression	NULL
vector	NULL
.	NULL

Repression	NULL
mediated	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
was	NULL
synergistic	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
HIV-1	NULL
LTR-CAT	NULL
reporter	NULL
(	NULL
1	NULL
)	NULL
,	NULL
25	NULL
ng	NULL
of	NULL
Tat	NULL
expression	NULL
vector	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
empty	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
expression	NULL
vector	NULL
,	NULL
CMV-YY1	NULL
,	NULL
or	NULL
CMV-LSF	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
the	NULL
repression	NULL
of	NULL
CAT	NULL
expression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
was	NULL
more	NULL
than	NULL
additive	NULL
.	NULL

Percent	NULL
acetylation	NULL
is	NULL
indicated	NULL
above	NULL
each	NULL
lane	NULL
.	NULL

INHIBITION	NULL
OF	NULL
HIV-1	NULL
BY	NULL
YYI	NULL
AND	NULL
LSF	NULL
-	NULL
9381	NULL
YY1	NULL
and	NULL
LSF	NULL
to	NULL
cooperate	NULL
in	NULL
function	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
described	NULL
.	NULL

Our	NULL
findings	NULL
suggest	NULL
that	NULL
LSF	NULL
allows	NULL
YY1	NULL
to	NULL
recognize	NULL
a	NULL
site	NULL
on	NULL
the	NULL
LTR	NULL
that	NULL
YY1	NULL
can	NULL
not	NULL
bind	NULL
by	NULL
itself	NULL
.	NULL

Anti-YY1	NULL
antibodies	NULL
completely	NULL
and	NULL
specifically	NULL
disrupt	NULL
RCS	NULL
complex	NULL
formation	NULL
.	NULL

However	NULL
,	NULL
bacterially	NULL
expressed	NULL
YY1	NULL
binds	NULL
weakly	NULL
to	NULL
the	NULL
RCS	NULL
,	NULL
suggesting	NULL
that	NULL
YY1	NULL
of	NULL
bacterial	NULL
origin	NULL
is	NULL
unable	NULL
to	NULL
bind	NULL
the	NULL
RCS	NULL
or	NULL
that	NULL
YY1	NULL
requires	NULL
a	NULL
cofactor	NULL
for	NULL
binding	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
bacterially	NULL
expressed	NULL
LSF	NULL
as	NULL
well	NULL
as	NULL
LSF	NULL
purified	NULL
from	NULL
nuclear	NULL
extract	NULL
can	NULL
bind	NULL
an	NULL
oligonucleotide	NULL
encompassing	NULL
the	NULL
RCS	NULL
in	NULL
EMSAs	NULL
(	NULL
14	NULL
,	NULL
28	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Further	NULL
,	NULL
anti-LSF	NULL
antibodies	NULL
completely	NULL
and	NULL
specifically	NULL
disrupt	NULL
RCS	NULL
complex	NULL
formation	NULL
.	NULL

These	NULL
observations	NULL
are	NULL
consistent	NULL
with	NULL
a	NULL
model	NULL
in	NULL
which	NULL
YY1	NULL
participates	NULL
in	NULL
RCS	NULL
complex	NULL
formation	NULL
through	NULL
both	NULL
direct	NULL
contact	NULL
with	NULL
LSF	NULL
and	NULL
a	NULL
DNA	NULL
site	NULL
(	NULL
s	NULL
)	NULL
within	NULL
the	NULL
RCS	NULL
.	NULL

This	NULL
model	NULL
has	NULL
precedent	NULL
in	NULL
YY1	NULL
function	NULL
in	NULL
other	NULL
promoters	NULL
.	NULL

The	NULL
human	NULL
papillomavirus	NULL
type	NULL
18	NULL
URR	NULL
promoter	NULL
is	NULL
regulated	NULL
by	NULL
YY1	NULL
,	NULL
but	NULL
YY1	NULL
requires	NULL
C/EBP-B	NULL
to	NULL
cooperatively	NULL
bind	NULL
a	NULL
site	NULL
in	NULL
the	NULL
human	NULL
papillomavirus	NULL
promoter	NULL
not	NULL
recognized	NULL
by	NULL
YY1	NULL
alone	NULL
(	NULL
3	NULL
)	NULL
.	NULL

YY1	NULL
can	NULL
directly	NULL
repress	NULL
transcription	NULL
;	NULL
it	NULL
binds	NULL
and	NULL
represses	NULL
the	NULL
AAV	NULL
P5	NULL
promoter	NULL
(	NULL
24	NULL
)	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
YY1	NULL
requires	NULL
a	NULL
second	NULL
protein	NULL
,	NULL
LSF	NULL
,	NULL
to	NULL
bind	NULL
the	NULL
RCS	NULL
within	NULL
the	NULL
HIV-1	NULL
LTR	NULL
and	NULL
that	NULL
binding	NULL
of	NULL
the	NULL
HIV-1	NULL
promoter	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
results	NULL
in	NULL
repression	NULL
of	NULL
transcription	NULL
.	NULL

However	NULL
,	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
demonstrated	NULL
a	NULL
direct	NULL
physical	NULL
interaction	NULL
between	NULL
YY1	NULL
and	NULL
LSF	NULL
or	NULL
a	NULL
biochemical	NULL
cooperation	NULL
in	NULL
binding	NULL
the	NULL
RCS	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
can	NULL
not	NULL
yet	NULL
exclude	NULL
other	NULL
models	NULL
,	NULL
such	NULL
as	NULL
those	NULL
involving	NULL
a	NULL
third	NULL
factor	NULL
.	NULL

Studies	NULL
to	NULL
explore	NULL
the	NULL
protein-protein	NULL
and	NULL
protein-DNA	NULL
interactions	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
are	NULL
underway	NULL
.	NULL

Three	NULL
transcription	NULL
factors	NULL
,	NULL
USF	NULL
,	NULL
LSF	NULL
(	NULL
LBP-1c/UBP-1/CP-2	NULL
)	NULL
,	NULL
and	NULL
TDP-43	NULL
,	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
HIV-1	NULL
LTR	NULL
within	NULL
the	NULL
-17	NULL
to	NULL
+27	NULL
region	NULL
that	NULL
is	NULL
also	NULL
recognized	NULL
by	NULL
YY1	NULL
(	NULL
8	NULL
,	NULL
9	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
19	NULL
,	NULL
29	NULL
)	NULL
.	NULL

USF	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
transcription	NULL
(	NULL
8	NULL
)	NULL
.	NULL

We	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
TDP-43	NULL
in	NULL
the	NULL
column	NULL
fractions	NULL
containing	NULL
the	NULL
RCS-binding	NULL
activity	NULL
.	NULL

As	NULL
inhibition	NULL
of	NULL
LTR	NULL
expression	NULL
is	NULL
not	NULL
seen	NULL
upon	NULL
the	NULL
overexpression	NULL
of	NULL
LSF	NULL
in	NULL
pCMv	NULL
-	NULL
(	NULL
ug	NULL
)	NULL
2.5	NULL
1.25	NULL
1.25	NULL
pCMv-YY1	NULL
1.25ug	NULL
-	NULL
+	NULL
-	NULL
+	NULL
pCMV-LSF	NULL
1.25ug	NULL
i	NULL
A	NULL
+	NULL
+	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Mutations	NULL
which	NULL
abolish	NULL
YY1	NULL
and	NULL
LSF	NULL
binding	NULL
abrograte	NULL
the	NULL
ability	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
to	NULL
repress	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
ng	NULL
of	NULL
ms	NULL
(	NULL
ABC	NULL
)	NULL
'-CAT	NULL
reporter	NULL
,	NULL
25	NULL
ng	NULL
of	NULL
Tat	NULL
expression	NULL
vector	NULL
(	NULL
10	NULL
)	NULL
,	NULL
and	NULL
empty	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
expression	NULL
vector	NULL
,	NULL
CMV-YY1	NULL
,	NULL
or	NULL
CMV-LSF	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
YY1	NULL
and	NULL
LSF	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
CAT	NULL
expression	NULL
.	NULL

9382	NULL
ROMERIO	NULL
ET	NULL
AL	NULL
.	NULL

cells	NULL
,	NULL
these	NULL
observations	NULL
lead	NULL
us	NULL
to	NULL
speculate	NULL
that	NULL
YY1	NULL
directly	NULL
mediates	NULL
transcriptional	NULL
repression	NULL
following	NULL
its	NULL
recruitment	NULL
and/or	NULL
stabilization	NULL
within	NULL
the	NULL
RCS	NULL
complex	NULL
by	NULL
LSF	NULL
.	NULL

Previously	NULL
,	NULL
we	NULL
reported	NULL
that	NULL
YY1	NULL
was	NULL
able	NULL
to	NULL
repress	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
LTR	NULL
expression	NULL
and	NULL
inhibit	NULL
HIV-1	NULL
virion	NULL
production	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
now	NULL
find	NULL
that	NULL
coexpression	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
synergistically	NULL
inhibits	NULL
Tat-activated	NULL
LTR	NULL
expression	NULL
and	NULL
virion	NULL
production	NULL
.	NULL

Promoter	NULL
mutations	NULL
which	NULL
block	NULL
RCS	NULL
complex	NULL
formation	NULL
abrogate	NULL
repression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
.	NULL

These	NULL
mutations	NULL
also	NULL
abolish	NULL
the	NULL
function	NULL
of	NULL
the	NULL
inducer	NULL
of	NULL
short	NULL
transcripts	NULL
(	NULL
23	NULL
)	NULL
.	NULL

However	NULL
Pessler	NULL
et	NULL
al	NULL
.	NULL

have	NULL
recently	NULL
reported	NULL
that	NULL
neither	NULL
YY1	NULL
nor	NULL
LSF	NULL
regulates	NULL
the	NULL
function	NULL
of	NULL
the	NULL
inducer	NULL
of	NULL
short	NULL
transcripts	NULL
,	NULL
and	NULL
they	NULL
attribute	NULL
that	NULL
function	NULL
to	NULL
a	NULL
novel	NULL
factor	NULL
,	NULL
FBI-1	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
through	NULL
which	NULL
YY1	NULL
and	NULL
LSF	NULL
repress	NULL
HIV-1	NULL
transcription	NULL
remains	NULL
to	NULL
be	NULL
studied	NULL
.	NULL

YY1	NULL
interacts	NULL
directly	NULL
with	NULL
cellular	NULL
enhancer	NULL
factors	NULL
such	NULL
as	NULL
Sp1	NULL
(	NULL
15	NULL
)	NULL
and	NULL
with	NULL
other	NULL
general	NULL
transcription	NULL
factors	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Such	NULL
interactions	NULL
may	NULL
mediate	NULL
repression	NULL
by	NULL
blocking	NULL
the	NULL
assembly	NULL
of	NULL
a	NULL
preinitiation	NULL
transcription	NULL
complex	NULL
or	NULL
by	NULL
inhibiting	NULL
the	NULL
processivity	NULL
of	NULL
an	NULL
assembled	NULL
complex	NULL
.	NULL

Alternatively	NULL
or	NULL
additionally	NULL
,	NULL
as	NULL
the	NULL
viral	NULL
activator	NULL
protein	NULL
Tat	NULL
can	NULL
interact	NULL
with	NULL
the	NULL
TATA-binding	NULL
protein	NULL
and	NULL
can	NULL
induce	NULL
phosphorylation	NULL
of	NULL
RNA	NULL
polymerase	NULL
II	NULL
,	NULL
YY1	NULL
and	NULL
LSF	NULL
may	NULL
inhibit	NULL
these	NULL
putative	NULL
activating	NULL
functions	NULL
of	NULL
Tat	NULL
.	NULL

Finally	NULL
,	NULL
several	NULL
groups	NULL
have	NULL
recently	NULL
reported	NULL
that	NULL
histone	NULL
acetylation	NULL
may	NULL
result	NULL
in	NULL
transcriptional	NULL
repression	NULL
(	NULL
20	NULL
)	NULL
.	NULL

YY1	NULL
may	NULL
act	NULL
by	NULL
bringing	NULL
a	NULL
histone	NULL
acetylase	NULL
to	NULL
the	NULL
promoter	NULL
and	NULL
inducing	NULL
an	NULL
inhibitory	NULL
modulation	NULL
of	NULL
chromatin	NULL
structure	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Repression	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
appears	NULL
to	NULL
some	NULL
degree	NULL
to	NULL
be	NULL
selective	NULL
for	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Under	NULL
conditions	NULL
that	NULL
significantly	NULL
inhibited	NULL
LTR	NULL
expression	NULL
,	NULL
coexpression	NULL
of	NULL
YY1	NULL
and	NULL
LSF	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
promiscuous	NULL
viral	NULL
promoter	NULL
(	NULL
SV40	NULL
early	NULL
)	NULL
or	NULL
of	NULL
a	NULL
constitutive	NULL
cellular	NULL
promoter	NULL
(	NULL
B-actin	NULL
)	NULL
.	NULL

While	NULL
other	NULL
cellular	NULL
processes	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
affected	NULL
by	NULL
YY1	NULL
and	NULL
LSF	NULL
,	NULL
the	NULL
unique	NULL
cooperation	NULL
of	NULL
these	NULL
factors	NULL
may	NULL
allow	NULL
specificity	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
expression	NULL
.	NULL

It	NULL
is	NULL
attractive	NULL
to	NULL
speculate	NULL
that	NULL
YY1	NULL
and	NULL
LSF	NULL
participate	NULL
in	NULL
cellular	NULL
pathways	NULL
opposing	NULL
those	NULL
signals	NULL
that	NULL
activate	NULL
lymphocytes	NULL
,	NULL
induce	NULL
IL-2	NULL
expression	NULL
,	NULL
upregulate	NULL
NF-kB	NULL
,	NULL
and	NULL
promote	NULL
HIV-1	NULL
replication	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Q.	NULL
Zhu	NULL
and	NULL
U.	NULL
Hansen	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
the	NULL
LSF	NULL
expression	NULL
vector	NULL
prior	NULL
to	NULL
publication	NULL
,	NULL
S.	NULL
Johnston	NULL
for	NULL
B-actin	NULL
luciferase	NULL
,	NULL
R.	NULL
Gay-nor	NULL
for	NULL
anti-TDP-43	NULL
,	NULL
M.	NULL
Sheffery	NULL
for	NULL
anti-CP-2	NULL
,	NULL
and	NULL
both	NULL
Y.	NULL
Shi	NULL
and	NULL
U.	NULL
Hansen	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
the	NULL
communication	NULL
of	NULL
unpublished	NULL
results	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
G.	NULL
K.	NULL
Lewis	NULL
,	NULL
R.	NULL
R.	NULL
Redfield	NULL
,	NULL
and	NULL
E.	NULL
C.	NULL
Tramont	NULL
for	NULL
their	NULL
support	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Adachi	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
S.	NULL
Koenig	NULL
,	NULL
T.	NULL
Folks	NULL
,	NULL
R.	NULL
Willey	NULL
,	NULL
A.	NULL
Rabson	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Production	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
syndrome-associated	NULL
retrovirus	NULL
in	NULL
human	NULL
and	NULL
nonhuman	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
infectious	NULL
molecular	NULL
clone	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

59:284-291	NULL
.	NULL

2	NULL
.	NULL

Ausubel	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
.	NULL

1995	NULL
.	NULL

Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

John	NULL
Wiley	NULL
and	NULL
Sons	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
3	NULL
.	NULL

Bauknecht	NULL
,	NULL
T.	NULL
,	NULL
F.	NULL
Jundt	NULL
,	NULL
I.	NULL
Herr	NULL
,	NULL
T.	NULL
Ocbler	NULL
,	NULL
H.	NULL
Delius	NULL
,	NULL
Y.	NULL
Shi	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
and	NULL
H.	NULL
zur	NULL
Hausen	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
switch	NULL
region	NULL
determines	NULL
the	NULL
cell-type-specific	NULL
positive	NULL
or	NULL
negative	NULL
action	NULL
of	NULL
YY1	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
papillomavirus	NULL
type	NULL
18	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:1-12	NULL
.	NULL

4	NULL
.	NULL

Bauknecht	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
See	NULL
,	NULL
and	NULL
Y.	NULL
Shi	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
novel	NULL
C/EBP	NULL
B-YY1	NULL
complex	NULL
controls	NULL
the	NULL
cell-type-specific	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
papillomavirus	NULL
type	NULL
18	NULL
upstream	NULL
regulatory	NULL
region	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:7695-7705	NULL
.	NULL

5	NULL
.	NULL

Chiang	NULL
,	NULL
C.-M.	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1995	NULL
.	NULL

Cloning	NULL
of	NULL
an	NULL
intrinsic	NULL
human	NULL
TFIID	NULL
subunit	NULL
that	NULL
interacts	NULL
with	NULL
multiple	NULL
transcriptional	NULL
activators	NULL
.	NULL

Science	NULL
267	NULL
:	NULL
531-536	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

.	NULL

Chun	NULL
,	NULL
T.-W.	NULL
,	NULL
D.	NULL
Finzi	NULL
,	NULL
J.	NULL
Margolick	NULL
,	NULL
K.	NULL
Chadwick	NULL
,	NULL
D.	NULL
Schwartz	NULL
,	NULL
and	NULL
R.	NULL
F.	NULL
Siliciano	NULL
.	NULL

1995	NULL
.	NULL

In	NULL
vivo	NULL
fate	NULL
of	NULL
HIV-1-infected	NULL
T	NULL
cells	NULL
:	NULL
quantitative	NULL
analysis	NULL
of	NULL
the	NULL
transition	NULL
to	NULL
stable	NULL
latency	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

1:1284-1290.	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
1990	NULL
.	NULL

Preparation	NULL
of	NULL
extracts	NULL
from	NULL
higher	NULL
eukaryotes	NULL
.	NULL

Meth-	NULL
ods	NULL
Enzymol	NULL
.	NULL

182:194-203.	NULL
.	NULL

Du	NULL
,	NULL
H.	NULL
,	NULL
A.	NULL
L.	NULL
Roy	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
transcription	NULL
factor	NULL
USF	NULL
stimulates	NULL
transcription	NULL
through	NULL
the	NULL
initiator	NULL
elements	NULL
of	NULL
the	NULL
HIV-1	NULL
and	NULL
the	NULL
Ad-ML	NULL
promoters	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:501-511.	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
K.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1987	NULL
.	NULL

Interactions	NULL
of	NULL
cellular	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3761-3770	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
W.	NULL
Phelps	NULL
,	NULL
L.	NULL
Feigenbaum	NULL
,	NULL
J.	NULL
M.	NULL
Ostrove	NULL
,	NULL
A.	NULL
Adachi	NULL
,	NULL
P.	NULL
M.	NULL
Howley	NULL
,	NULL
G.	NULL
Khoury	NULL
,	NULL
H.	NULL
S.	NULL
Ginsberg	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1986	NULL
.	NULL

Trans-activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
sequence	NULL
by	NULL
DNA	NULL
viruses	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:9759-9763	NULL
.	NULL

Huang	NULL
,	NULL
H.-C.	NULL
,	NULL
R.	NULL
Sundseth	NULL
,	NULL
and	NULL
U.	NULL
Hansen	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
LSF	NULL
binds	NULL
two	NULL
variant	NULL
bipartite	NULL
sites	NULL
within	NULL
the	NULL
SV40	NULL
late	NULL
promoter	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:287-298	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
N.	NULL
Duchange	NULL
.	NULL

1988	NULL
.	NULL

Structural	NULL
arrangements	NULL
of	NULL
transcription	NULL
control	NULL
domains	NULL
within	NULL
the	NULL
5'-untranslated	NULL
leader	NULL
regions	NULL
of	NULL
the	NULL
HIV-1	NULL
and	NULL
HIV-2	NULL
promoters	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

21101-1114	NULL
.	NULL

Kadonaga	NULL
,	NULL
J.	NULL
T.	NULL
1991	NULL
.	NULL

Purification	NULL
of	NULL
sequence-specific	NULL
binding	NULL
proteins	NULL
by	NULL
DNA	NULL
affinity	NULL
chromatography	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

208:10-23	NULL
.	NULL

Kato	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Horikoshi	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1991	NULL
.	NULL

Repression	NULL
of	NULL
HIV-1	NULL
transcription	NULL
by	NULL
a	NULL
cellular	NULL
protein	NULL
.	NULL

Science	NULL
251:1476-1479	NULL
.	NULL

Lee	NULL
,	NULL
J.-S.	NULL
,	NULL
K.	NULL
M.	NULL
Galvin	NULL
,	NULL
and	NULL
Y.	NULL
Shi	NULL
.	NULL

1993	NULL
.	NULL

Evidence	NULL
for	NULL
physical	NULL
interaction	NULL
between	NULL
the	NULL
zinc-finger	NULL
transcription	NULL
factors	NULL
YY1	NULL
and	NULL
Sp1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:6145-6149	NULL
.	NULL

Lim	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
S.	NULL
L.	NULL
Swendeman	NULL
,	NULL
and	NULL
M.	NULL
Sheffery	NULL
.	NULL

1992	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
the	NULL
«	NULL
-globin	NULL
transcription	NULL
factor	NULL
CP2	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:828-835	NULL
.	NULL

Liu	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
A.	NULL
Thompson	NULL
,	NULL
S.	NULL
Wagner	NULL
,	NULL
M.	NULL
E.	NULL
Greenberg	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1993	NULL
.	NULL

Activating	NULL
transcription	NULL
factor-1	NULL
can	NULL
mediate	NULL
Ca**-	NULL
and	NULL
cAMP	NULL
ible	NULL
transcriptional	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:6714-6720	NULL
.	NULL

Margolis	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
M.	NULL
Somasundaran	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1994	NULL
.	NULL

Human	NULL
transcription	NULL
factor	NULL
YY1	NULL
represses	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transcription	NULL
and	NULL
virion	NULL
production	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:905-910	NULL
.	NULL

Ou	NULL
,	NULL
S.-H	NULL
.	NULL

I.	NULL
,	NULL
F.	NULL
Wu	NULL
,	NULL
D.	NULL
Harrich	NULL
,	NULL
L.	NULL
F.	NULL
Garcia-Martinez	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1995	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
novel	NULL
cellular	NULL
protein	NULL
,	NULL
TDP-43	NULL
,	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
TAR	NULL
DNA	NULL
sequence	NULL
motifs	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:3584-3596	NULL
.	NULL

Pazin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Kadonaga	NULL
.	NULL

1997	NULL
.	NULL

What	NULL
's	NULL
up	NULL
and	NULL
down	NULL
with	NULL
histone	NULL
deacetylation	NULL
and	NULL
transcription	NULL
?	NULL

Cell	NULL
89:325-328	NULL
.	NULL

Pessler	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
S.	NULL
Pendergrast	NULL
,	NULL
and	NULL
N.	NULL
Hernandez	NULL
.	NULL

1997	NULL
.	NULL

Purification	NULL
and	NULL
characterization	NULL
of	NULL
FBI-1	NULL
,	NULL
a	NULL
cellular	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
inducer	NULL
of	NULL
short	NULL
transcripts	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
:	NULL
3786-3798	NULL
.	NULL

Rio	NULL
,	NULL
D.	NULL
,	NULL
A.	NULL
Robbins	NULL
,	NULL
R.	NULL
Myers	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1980	NULL
.	NULL

Regulation	NULL
of	NULL
simian	NULL
virus	NULL
40	NULL
early	NULL
transcription	NULL
in	NULL
vitro	NULL
by	NULL
a	NULL
purified	NULL
tumor	NULL
antigen	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
77:5706-5710	NULL
.	NULL

Sheldon	NULL
,	NULL
M.	NULL
,	NULL
R.	NULL
Rat	NULL
bapathy	NULL
,	NULL
and	NULL
N.	NULL
Her	NULL
dez	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
inducer	NULL
of	NULL
short	NULL
transcripts	NULL
,	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transcriptional	NULL
element	NULL
that	NULL
activates	NULL
the	NULL
synthesis	NULL
of	NULL
short	NULL
RNAs	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:1251-1263	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
,	NULL
E.	NULL
Seto	NULL
,	NULL
L.-S.	NULL
Chang	NULL
,	NULL
and	NULL
T.	NULL
Shenk	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
YY1	NULL
,	NULL
a	NULL
human	NULL
GLI-Kriippel-related	NULL
protein	NULL
,	NULL
and	NULL
relief	NULL
of	NULL
repression	NULL
by	NULL
adenovirus	NULL
E1A	NULL
protein	NULL
.	NULL

Cell	NULL
67:377-388.	NULL
.	NULL

Volker	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
L.	NULL
E.	NULL
Rameb	NULL
,	NULL
J.	NULL
DeCaprio	NULL
,	NULL
and	NULL
U.	NULL
Hansen	NULL
.	NULL

1997	NULL
.	NULL

Mitogenic	NULL
stimulation	NULL
of	NULL
resting	NULL
T	NULL
cells	NULL
causes	NULL
rapid	NULL
phosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
LSF	NULL
and	NULL
increased	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

11:1-12	NULL
.	NULL

Williams	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
S.	NULL
A.	NULL
Johnston	NULL
,	NULL
M.	NULL
Riedy	NULL
,	NULL
M.	NULL
J.	NULL
DeVit	NULL
,	NULL
S.	NULL
G.	NULL
McElligott	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Sanford	NULL
.	NULL

1991	NULL
.	NULL

Introduction	NULL
of	NULL
foreign	NULL
genes	NULL
into	NULL
tissues	NULL
of	NULL
living	NULL
mice	NULL
by	NULL
DNA-coated	NULL
microprojectiles	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:2726-2730	NULL
.	NULL

Yang	NULL
,	NULL
W.-M.	NULL
,	NULL
C.	NULL
Inouye	NULL
,	NULL
Y.	NULL
Zeng	NULL
,	NULL
D.	NULL
Bearss	NULL
,	NULL
and	NULL
E.	NULL
Seto	NULL
.	NULL

1996	NULL
.	NULL

Transcriptional	NULL
repression	NULL
by	NULL
YY1	NULL
is	NULL
mediated	NULL
by	NULL
interaction	NULL
with	NULL
a	NULL
mammalian	NULL
homolog	NULL
of	NULL
the	NULL
yeast	NULL
global	NULL
regulator	NULL
RPD3	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:12845-12850	NULL
.	NULL

Yoon	NULL
,	NULL
J.-B	NULL
.	NULL

,	NULL
G.	NULL
Li	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Roeder	NULL
.	NULL

1994	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
family	NULL
of	NULL
related	NULL
cellular	NULL
transcription	NULL
factors	NULL
which	NULL
can	NULL
modulate	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
transcription	NULL
in	NULL
vitro	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:1776-1785	NULL
.	NULL

Zhong	NULL
,	NULL
F.	NULL
,	NULL
S.	NULL
L.	NULL
Swendeman	NULL
,	NULL
W.	NULL
Popik	NULL
,	NULL
P.	NULL
M.	NULL
Pitha	NULL
,	NULL
and	NULL
M.	NULL
Sheffery	NULL
.	NULL

1994	NULL
.	NULL

Evidence	NULL
that	NULL
levels	NULL
of	NULL
the	NULL
dimeric	NULL
cellular	NULL
transcription	NULL
factor	NULL
CP-2	NULL
play	NULL
little	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
vivo	NULL
or	NULL
following	NULL
superinfection	NULL
with	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:21269-21276	NULL
.	NULL

Zhou	NULL
,	NULL
Q.	NULL
,	NULL
R.	NULL
W.	NULL
Gedrich	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Engel	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
repression	NULL
of	NULL
the	NULL
c-fos	NULL
gene	NULL
by	NULL
YY1	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
direct	NULL
interaction	NULL
with	NULL
ATF/	NULL
CREB	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4323-4330	NULL
.	NULL

